Skip to main content

HER2+ Metastatic Breast Cancer

Elisa Agostinetto, MD, Institut Jules Bordet
Videos
02/28/2022
In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.
In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.
In part 2 of this series, Dr...
02/28/2022
Oncology
Dr Harbeck
Videos
06/07/2021
Nadia Harbeck, MD, PhD, discusses results from the ADAPT-HR-/HER2+ trial on early breast cancer.
Nadia Harbeck, MD, PhD, discusses results from the ADAPT-HR-/HER2+ trial on early breast cancer.
Nadia Harbeck, MD,...
06/07/2021
Oncology
Mariana Chavez Mac Gregor
Videos
04/19/2021
Mariana Chavez Mac Gregor, MD, MSC, University of Texas, MD Anderson Cancer Center, highlights her approach to treating patients with metastatic HER2 + breast cancer.
Mariana Chavez Mac Gregor, MD, MSC, University of Texas, MD Anderson Cancer Center, highlights her approach to treating patients with metastatic HER2 + breast cancer.
Mariana Chavez Mac Gregor, MD,...
04/19/2021
Oncology
Dr George Highlights Advancements in HER2+ Breast Cancer Therapy
Videos
04/11/2021
Mridula George, MD, discusses the addition of HER2 targeted agents within the last 2 decades that have been studied in the metastatic, adjuvant, and the neoadjuvant setting.
Mridula George, MD, discusses the addition of HER2 targeted agents within the last 2 decades that have been studied in the metastatic, adjuvant, and the neoadjuvant setting.
Mridula George, MD, discusses...
04/11/2021
Oncology